The JAK‐STAT3 pathway has been experimentally activated in CLL cells by stimulation of the B‐cell receptor, while treatment of these cells with the JAK1/2 inhibitor ruxolitinib has been found to inhibit STAT3 phosphorylation and to induce apoptosis of the cells 24. Here, STAT3 is linked to B-cell chronic lymphocytic leukemia.